- Home
- VOD vs ONC Comparison
VOD vs ONC Comparison
Compare VOD & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VOD | ONC |
|---|---|---|
| Founded | 1984 | 2010 |
| Country | United Kingdom | Switzerland |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.4B | 34.8B |
| IPO Year | 1988 | N/A |
Fundamental Metrics
Financial Performance| Metric | VOD | ONC |
|---|---|---|
| Price | $13.10 | $311.76 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | N/A | ★ $369.50 |
| AVG Volume (30 Days) | ★ 4.5M | 281.7K |
| Earning Date | 05-12-2026 | 11-06-2025 |
| Dividend Yield | ★ 3.72% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.58 |
| Revenue | ★ $45,501,583,954.00 | $4,972,687,000.00 |
| Revenue This Year | $11.65 | $895.40 |
| Revenue Next Year | $2.80 | $22.04 |
| P/E Ratio | ★ N/A | $534.14 |
| Revenue Growth | 4.79 | ★ 50.43 |
| 52 Week Low | $8.00 | $172.67 |
| 52 Week High | $13.07 | $385.22 |
Technical Indicators
Market Signals| Indicator | VOD | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 69.69 | 41.88 |
| Support Level | $12.83 | $306.61 |
| Resistance Level | $12.96 | $318.12 |
| Average True Range (ATR) | 0.13 | 8.43 |
| MACD | 0.03 | -0.78 |
| Stochastic Oscillator | 98.53 | 36.90 |
Price Performance
Historical ComparisonAbout VOD Vodafone Group Plc
Vodafone operates mobile and fixed-line networks and businesses across Europe, Africa, and the Middle East. Its largest market is Germany, where it is the second mobile operator after Deutsche Telekom and owns two cable network after acquiring Kabel Deutschland in 2013 and Liberty Global Germany in 2019. In the UK Vodafone merger with CK Hutchison in 2024, consolidating the mobile market. It also divested its Spanish and Italian divisions in that same year, given their low returns on invested capital.
About ONC BeiGene Ltd. American Depositary Shares
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.